Chronic Lymphocytic Leukemia
FDA Approval Sought for Maintenance Ofatumumab in CLL
Read More >>
View Free CME from PER >>
Ibrutinib Expert Ponders Prospects for Novel Combinations in CLL
Expanded Idelalisib Indication in CLL on Horizon After Positive Phase III Combo Trial With Ofatumumab
HELIOS Ibrutinib Data ‘Practice Changing’ for CLL, Says Chanan-Khan
Ofatumumab/Chemo Combo Improves PFS By Over 50% in CLL
Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study
View More >>
See the latest in research and cutting edge developments from our partner institutions
- A Network of Your Peers
View more >>
Dr. Jeffrey Jones on Idelalisib Combinations in CLL
Preventing Infusion Reactions With CD20 Antibodies in CLL
Role of B-Cell Receptor Signaling Inhibitors in CLL
Changing Treatment Landscape in CLL
Rituximab, Obinutuzumab, and Ofatumumab in CLL
In this segment, Myron Czuczman, MD, outlines the different roles of the various monoclonal antibodies used in the treatment of chronic lymphocytic leukemia (CLL).
Closing Thoughts: A Cure in Sight for CLL?
Panelists provide their final thoughts on CLL/NHL ad related hematology diseases.
OncLive News Network
The OncLive News Network updates viewers on breaking news, clinical trial results, FDA approvals, and offers an inside look into leading cancer centers and clinical trials.
View Now >>
2015 ASCO Annual Meeting Highlights
Laura Jones recaps major findings from the 2015 ASCO Annual Meeting, including phase III findings for new treatments in melanoma, chronic lymphocytic leukemia, lung cancer, breast cancer, and multiple myeloma.
Most Popular Right Now
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.